A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this first-in human study is to demonstrate systemic and local tolerability
and investigate pharmacokinetics of LFX453 after multiple topical applications in healthy
subjects.
The current study has been designed with three distinct parts. Part 1 focuses on safety and
tolerability of once daily application on the back, prior to moving forward and assessing the
safety and tolerability in more sensitive treatment areas in Part 2 or twice daily
application in Part 3.